Skip to main content

Table 1 Patient characteristics during the baseline period

From: In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility

Characteristic baseline subgroupPlacebo (N = 476)Reslizumab (N = 477)
Mean age (SD), years47.1 (14.3)46.5 (13.8)
Females, n (%)311 (65)286 (60)
Mean body mass index (SD), kg/m227.5 (5.7)27.4 (5.8)
Oral corticosteroid use, n (%)73 (15)73 (15)
LABA use, n (%)383 (80)397 (83)
High-dose ICSa use, n (%)208 (44)203 (43)
Mean FEV1 (SD), mL1965 (734)2008 (763)
 EOS < 150 cells/µL1947 (643)2317 (834)
 EOS 150 to < 400 cells/µL2101 (759)2032 (734)
 EOS 400 to < 700 cells/µL1997 (795)2091 (785)
 EOS ≥ 700 cells/µL1860 (655)1846 (710)
 FEV1 reversibility < 14%2258 (735)1975 (754)
 FEV1 reversibility 14 to < 16%2187 (666)2180 (659)
 FEV1 reversibility 16 to 20%1944 (838)2045 (821)
 FEV1 reversibility ≥ 20%1841 (678)1979 (763)
Mean FEV1 predicted (SD),  %66.5 (19.4)66.9 (20.0)
Mean FEV1 reversibility (SD), %27.5 (21.1)27.0 (15.8)
Mean FVC (SD), mL3008 (1030)3070 (1010)
Mean blood EOS (SD), cells/µL655 (637)654 (621)
Mean age of asthma onset (SD), years27.8 (17.9)27.3 (18.4)
  1. aHigh-dose ICS use was defined as when one of the following was true at enrolment: fluticasone > 500 µg/day, mometasone > 440 µg/day, budesonide > 800 µg/day, ciclesonide > 320 µg/day, beclomethasone > 400 µg/day or triamcinolone > 2000 µg/day
  2. EOS eosinophil, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting beta agonist, SD standard deviation